ES2185909T3 - Tratamiento y prevencion de los efectos adversos de especies de oxigeno reactivo. - Google Patents

Tratamiento y prevencion de los efectos adversos de especies de oxigeno reactivo.

Info

Publication number
ES2185909T3
ES2185909T3 ES97905855T ES97905855T ES2185909T3 ES 2185909 T3 ES2185909 T3 ES 2185909T3 ES 97905855 T ES97905855 T ES 97905855T ES 97905855 T ES97905855 T ES 97905855T ES 2185909 T3 ES2185909 T3 ES 2185909T3
Authority
ES
Spain
Prior art keywords
reactive oxygen
oxygen species
prevention
treatment
adverse effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905855T
Other languages
English (en)
Inventor
Lawrence D Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Application granted granted Critical
Publication of ES2185909T3 publication Critical patent/ES2185909T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

PUEDEN UTILIZARSE BUCILAMINA Y N-2,2-DIMETIL-3MERCAPTOPROPIONIL)-L-CISTEINA O COMPUESTOS RELACIONADOS PARA EVITAR DAÑOS A TEJIDOS VIVOS QUE SE DERIVEN DE LA FORMACION O PRESENCIA DE ESPECIES REACTIVAS DE OXIGENO. ESTAS ESPECIES REACTIVAS DEL OXIGENO SE FORMAN CUANDO EL TEJIDO SE VUELVE POR PRIMERA VEZ HIPOXICO DEBIDO A LA INTERRUPCION DEL FLUJO SANGUINEO Y LUEGO SE REOXIGENA MEDIANTE LA RESTAURACION DEL FLUJO SANGUINEO. EN PARTICULAR LA INVENCION SE REFIERE A LA ADMINISTRACION DE BUCILAMINA Y DE N-2,2-DIMETIL-3MERCAPTOPROPIONIL)-L-CISTEINA ANTES O COINCIDIENDO CON LA REPERFUSION PARA EVITAR DAÑOS AL MIOCARDIO QUE SE DERIVAN DE LA FORMACION DE ESPECIES REACTIVAS DEL OXIGENO. TAMBIEN SE PRESENTAN APLICACIONES DE ESTOS COMPUESTOS PARA LESIONES CELULARES SIMILARES RELACIONADAS CON LA ISQUEMIA U OTROS ORGANOS.
ES97905855T 1996-02-09 1997-02-07 Tratamiento y prevencion de los efectos adversos de especies de oxigeno reactivo. Expired - Lifetime ES2185909T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/598,926 US5670545A (en) 1996-02-09 1996-02-09 Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species

Publications (1)

Publication Number Publication Date
ES2185909T3 true ES2185909T3 (es) 2003-05-01

Family

ID=24397503

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905855T Expired - Lifetime ES2185909T3 (es) 1996-02-09 1997-02-07 Tratamiento y prevencion de los efectos adversos de especies de oxigeno reactivo.

Country Status (13)

Country Link
US (2) US5670545A (es)
EP (1) EP0910355B1 (es)
JP (1) JP2001500104A (es)
CN (1) CN1097457C (es)
AT (1) ATE227125T1 (es)
AU (1) AU713754B2 (es)
CA (1) CA2246236C (es)
CZ (1) CZ291763B6 (es)
DE (1) DE69716914T2 (es)
EA (2) EA001800B1 (es)
ES (1) ES2185909T3 (es)
HU (1) HUP9901969A3 (es)
WO (1) WO1997028792A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
EP1475434A1 (en) * 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US20090263780A1 (en) * 2008-04-17 2009-10-22 Yanming Wang Organ preservation fluid
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
EP2736536A4 (en) 2011-07-27 2015-03-11 Univ Kansas TEMPLATE ISLAND CELLS AND SMALL ISLAND CELL PATTERNS FOR THE TREATMENT OF DIABETES
WO2023184031A1 (en) * 2022-03-30 2023-10-05 Revive Therapeutics Ltd Method and use of bucillamine in the prevention and treatment of stroke

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51148090A (en) * 1975-06-12 1976-12-18 Santen Pharmaceut Co Ltd Process for stabilizing an aqueous lysozyme solution
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives
US4053651A (en) * 1976-05-10 1977-10-11 E. R. Squibb & Sons, Inc. Compounds and method for alleviating angiotensin related hypertension
JPS545916A (en) * 1977-06-17 1979-01-17 Santen Pharmaceutical Co Ltd Novel cystein derivative
JPS5912119B2 (ja) * 1977-10-29 1984-03-21 参天製薬株式会社 アミノ酸誘導体の製造方法
JPS5551021A (en) * 1978-10-11 1980-04-14 Santen Pharmaceut Co Ltd Remedy for hepatic disorder
JPS6011888B2 (ja) * 1978-10-11 1985-03-28 参天製薬株式会社 リウマチ疾患治療薬
JPS6058908B2 (ja) * 1978-10-11 1985-12-23 参天製薬株式会社 システイン誘導体
JPS5756454A (en) * 1980-09-20 1982-04-05 Santen Pharmaceut Co Ltd Disulfide type cysteine derivative
US5292926A (en) * 1988-01-25 1994-03-08 Santen Pharmaceutical Co., Ltd. Cysteine derivatives
JPH04154714A (ja) * 1990-10-17 1992-05-27 Shiseido Co Ltd 毛髪還元剤及び毛髪化粧料
JP2816500B2 (ja) * 1990-10-17 1998-10-27 参天製薬株式会社 抗骨粗鬆剤
JP3066608B2 (ja) * 1991-01-16 2000-07-17 参天製薬株式会社 腎疾患治療剤
JP2814033B2 (ja) * 1992-01-10 1998-10-22 参天製薬株式会社 シスチン尿症治療剤
JP2843955B2 (ja) * 1992-08-01 1999-01-06 参天製薬株式会社 抗白内障剤
JP2899740B2 (ja) * 1994-02-08 1999-06-02 参天製薬株式会社 炎症性腸疾患治療剤

Also Published As

Publication number Publication date
EP0910355A1 (en) 1999-04-28
CZ291763B6 (cs) 2003-05-14
HUP9901969A2 (hu) 1999-11-29
US5756547A (en) 1998-05-26
AU713754B2 (en) 1999-12-09
DE69716914D1 (de) 2002-12-12
EP0910355B1 (en) 2002-11-06
CZ246998A3 (cs) 1998-11-11
EA001800B1 (ru) 2001-08-27
CA2246236C (en) 2006-12-19
EP0910355A4 (es) 1999-04-28
CN1097457C (zh) 2003-01-01
HUP9901969A3 (en) 2001-08-28
DE69716914T2 (de) 2003-07-03
JP2001500104A (ja) 2001-01-09
US5670545A (en) 1997-09-23
EA199800665A1 (ru) 1999-08-26
CA2246236A1 (en) 1997-08-14
CN1210461A (zh) 1999-03-10
EA200000762A1 (ru) 2001-04-23
AU2264497A (en) 1997-08-28
WO1997028792A1 (en) 1997-08-14
ATE227125T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
DK0726768T3 (da) Anvendelse af nitrogenoxidfrigørende forbindelser til fremstillingen af et medikament til beskyttelse i iskæmisk reperfusio
SE8701921L (sv) Ny farmaceutisk anvendning
Gallagher Protection by antioxidants against lethal doses of carbon tetrachloride
DE3864020D1 (de) Anordnung zur beseitigung von aktiven mitteln, oertlich verwendet gegen feste tumoren.
ES2038184T3 (es) Un procedimiento para preparar un compuesto de imidazo(4,5-b)piridina.
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
FI880464A0 (fi) Bekaempningsmedel mot tandplaque och -karies.
ES2063365T3 (es) Composiciones anticoagulantes basadas en el factor xa.
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
ES2185909T3 (es) Tratamiento y prevencion de los efectos adversos de especies de oxigeno reactivo.
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
ES2040809T3 (es) Procedimiento de transformacion microbiologica de substancias nocivas con contenido de azufre en gases de escape.
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
DE602006021290D1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
ES2180933T3 (es) Inhibidor de la serina-proteasa.
ATE290396T1 (de) Neue verwendung von hypoosmotischen salinelösungen und darauf basierendem medikament
EP0150792A3 (en) Drugs and the use of poorly soluble compounds of calcium and/or magnesium as drugs
ES2161932T3 (es) Membrana esterilizable con calor.
ES2150907T3 (es) Derivados de aminoacidos.
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
Jacobsen et al. The effect of scalding on the content of kininogen and kininase in limb lymph
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.